Tag: clinical trials

Integrating Deviation Documentation Into EDC, CTMS and eTMF Systems

Posted on By digi

Integrating Deviation Documentation Into EDC, CTMS and eTMF Systems Integrating Deviation Documentation Into EDC, CTMS and eTMF Systems The successful execution of clinical trials encompasses a multitude of protocols and regulatory environments globally, with the aim to ensure patient safety and data integrity. One of the crucial aspects within this realm is the management of…

Read More “Integrating Deviation Documentation Into EDC, CTMS and eTMF Systems” »

Documentation & Reporting Workflows

Common Pitfalls in Results Posting & Timelines—and How to Avoid Costly Findings

Posted on By digi

Common Pitfalls in Results Posting & Timelines—and How to Avoid Costly Findings Common Pitfalls in Results Posting & Timelines—and How to Avoid Costly Findings In the field of clinical trials, the significance of transparent results posting and adherence to timelines cannot be overstated. The polarix clinical trial serves as an exemplary case, illustrating the need…

Read More “Common Pitfalls in Results Posting & Timelines—and How to Avoid Costly Findings” »

Results Posting & Timelines

Aligning Results Posting & Timelines With ICH, GCP and Transparency Regulations

Posted on By digi

Aligning Results Posting & Timelines With ICH, GCP and Transparency Regulations Aligning Results Posting & Timelines With ICH, GCP and Transparency Regulations In the evolving landscape of clinical research, the necessity for transparent reporting of clinical trial results has gained paramount importance. Regulatory bodies across the globe emphasize a commitment to transparency, which fosters public…

Read More “Aligning Results Posting & Timelines With ICH, GCP and Transparency Regulations” »

Results Posting & Timelines

Investigator’s Brochure (IB) Authoring & Updates for Oncology, Rare Disease and High-Risk Therapeutic Areas

Posted on By digi

Investigator’s Brochure (IB) Authoring & Updates for Oncology, Rare Disease and High-Risk Therapeutic Areas Investigator’s Brochure (IB) Authoring & Updates for Oncology, Rare Disease and High-Risk Therapeutic Areas The Investigator’s Brochure (IB) serves as a critical document in the context of clinical trials, especially for oncology, rare disease, and high-risk therapeutic areas. The IB not…

Read More “Investigator’s Brochure (IB) Authoring & Updates for Oncology, Rare Disease and High-Risk Therapeutic Areas” »

Investigator’s Brochure (IB) Authoring & Updates

End-to-End Deviation Workflow: From Site Detection to Sponsor Assessment

Posted on By digi

End-to-End Deviation Workflow: From Site Detection to Sponsor Assessment End-to-End Deviation Workflow: From Site Detection to Sponsor Assessment In clinical trial management, adherence to protocols is paramount. However, protocol deviations can occur and must be effectively documented and reported. In this in-depth guide, we will explore the end-to-end deviation workflow, focusing on regulatory compliance in…

Read More “End-to-End Deviation Workflow: From Site Detection to Sponsor Assessment” »

Documentation & Reporting Workflows

Building Deviation Forms, Logs and eTools That Capture What Regulators Expect

Posted on By digi

Building Deviation Forms, Logs and eTools That Capture What Regulators Expect Building Deviation Forms, Logs and eTools That Capture What Regulators Expect In the realm of clinical trials, managing protocol deviations is critical to ensuring compliance with regulatory frameworks such as those established by the FDA, EMA, and MHRA. This article serves as a step-by-step…

Read More “Building Deviation Forms, Logs and eTools That Capture What Regulators Expect” »

Documentation & Reporting Workflows

How to Design Results Posting & Timelines That Meets FDA, EMA and MHRA Expectations

Posted on By digi

How to Design Results Posting & Timelines That Meets FDA, EMA and MHRA Expectations The design of results posting and timelines is a crucial aspect of clinical trials, particularly for ensuring compliance with regulatory agencies such as the FDA, EMA, and MHRA. As professionals in clinical operations, regulatory affairs, and medical affairs, it is essential…

Read More “How to Design Results Posting & Timelines That Meets FDA, EMA and MHRA Expectations” »

Results Posting & Timelines

Results Posting & Timelines in Practice: Step-by-Step Guide for Sponsors and CROs

Posted on By digi

Results Posting & Timelines in Practice: Step-by-Step Guide for Sponsors and CROs In the increasingly regulated landscape of clinical research, the transparency of findings is more crucial than ever. With the focus on precision medicine and results dissemination, particularly within melanoma clinical trials, understanding the protocols for results posting and timelines is essential for sponsors…

Read More “Results Posting & Timelines in Practice: Step-by-Step Guide for Sponsors and CROs” »

Results Posting & Timelines

Quality Control and Peer Review Processes for High-Stakes Investigator’s Brochure (IB) Authoring & Updates

Posted on By digi

Quality Control and Peer Review Processes for High-Stakes Investigator’s Brochure (IB) Authoring & Updates Quality Control and Peer Review Processes for High-Stakes Investigator’s Brochure (IB) Authoring & Updates The Investigator’s Brochure (IB) is an essential document in clinical trials, as it provides comprehensive information about a drug or device being tested. As a high-stakes document,…

Read More “Quality Control and Peer Review Processes for High-Stakes Investigator’s Brochure (IB) Authoring & Updates” »

Investigator’s Brochure (IB) Authoring & Updates

Case Studies: Deviation Misclassification That Triggered Regulatory Findings

Posted on By digi

Case Studies: Deviation Misclassification That Triggered Regulatory Findings In the ever-evolving landscape of clinical trials, comprehension of protocol deviations and the nuances distinguishing them from violations is critical. Regulatory authorities, such as the FDA, EMA, and MHRA, scrutinize primary data for compliance. Case studies illustrating misclassifications of deviations will provide valuable insights to clinical operations,…

Read More “Case Studies: Deviation Misclassification That Triggered Regulatory Findings” »

Definitions: Deviation vs. Violation